Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Preeclampsia Drugs Market Forecast: Value Set To Climb From $1.51 Billion To $2.37 Billion#_x000D_
The preeclampsia drugs market size has seen substantial growth in recent years. Its value is expected to rise from $1.37 billion in 2025 to $1.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.6%. In previous periods, this expansion was largely due to factors such as restricted knowledge of preeclampsia management, an over-reliance on traditional treatments, a scarcity of advanced monitoring technologies, inadequate hospital infrastructure, and low investment in maternal health medications._x000D_
_x000D_
The preeclampsia drugs market is projected to expand significantly over the coming years. It is anticipated to reach a valuation of $2.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. This expansion during the projection period stems from progress in pharmaceutical formulations, broader healthcare infrastructure, a greater need for outpatient maternal services, the incorporation of digital health technologies, and enhanced research and development efforts in precision medicine for gestational complications. Key developments anticipated within this timeframe involve a higher occurrence of preeclampsia in pregnant individuals, the creation of new antihypertensive medications, a strengthened emphasis on monitoring maternal and fetal health, the expansion of distribution channels through hospital pharmacies and specialized clinics, and the use of combination therapies for more serious instances._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Preeclampsia Drugs Market Growth Backed By Core Demand Fundamentals#_x000D_
The increasing incidence of diabetes among pregnant women is anticipated to boost the preeclampsia drug market. Diabetes is a chronic metabolic condition characterized by elevated blood glucose levels, while preeclampsia is a serious pregnancy-related complication involving high blood pressure and organ damage. Metformin, a medicine for preeclampsia, is commonly prescribed to pregnant women experiencing preterm preeclampsia. For example, in June 2024, the National Health Service, a UK-based government department, reported that in 2023, an additional 549,000 individuals in England were identified as being at risk of developing type 2 diabetes. This brought the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330, marking a significant increase compared to 3,065,825 in 2022, which represents a rise of nearly 20%. Consequently, the growing number of diabetes cases among pregnant women will drive the preeclampsia drug market._x000D_
_x000D_
#Preeclampsia Drugs Market Segment Performance And Emerging Opportunities#_x000D_
The preeclampsia drugs market covered in this report is segmented – _x000D_
_x000D_
1) By Type: Mild Preeclampsia, Severe Preeclampsia_x000D_
2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication_x000D_
3) By Route of Administration: Oral, Parenteral, Other Route of Administration_x000D_
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels_x000D_
5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Mild Preeclampsia: Blood Pressure Management_x000D_
2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy_x000D_
_x000D_
#Preeclampsia Drugs Market Growth Trends Reshaping The Competitive Landscape#_x000D_
Major companies in the preeclampsia medicine market are concentrating on developing advanced therapies, such as small interfering RNA (siRNA) treatments, to address critical unmet medical needs through novel mechanisms of action. Investigational siRNA therapies are a class of medications designed to silence or switch off specific genes responsible for causing a disease, offering a targeted treatment approach. For instance, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical firm, announced that the Food and Drug Administration (FDA) had approved an investigational new drug (IND) application for CBP-4888, Comanche’s unique siRNA treatment for preeclampsia. CBP-4888 is an siRNA therapy administered subcutaneously that reduces the synthesis of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The primary cause of preeclampsia is the placenta’s overproduction of the protein sFLT1, which then enters the mother’s circulation. CBP-4888 has the potential to alleviate preeclampsia symptoms, such as high blood pressure and organ damage, and may facilitate the safe extension of pregnancy._x000D_
_x000D_
#Preeclampsia Drugs Market Key Players: Which Companies Lead Industry Competition?#_x000D_
Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Boehringer Ingelheim Group, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals Limited, Union Chimique Belge SA, Kyowa Kirin Co Ltd, Comanche Biopharma Corp _x000D_
_x000D_
#View The Full Preeclampsia Drugs Market Report:#_x000D_
_x000D_
#Preeclampsia Drugs Market Regional Analysis And Top Geography#_x000D_
North America was the largest region in the preeclampsia drugs market in 2025. The regions covered in the preeclampsia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
